NeuroMetrix Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-the-Counter Pain Relief Device
22 sept. 2020 07h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the launch of the Quell Watch App, now available for download from the Apple App store. Quell is a...
NeuroMetrix Announces Issuance of New U.S. Patent for Quell® Wearable Technology
21 sept. 2020 13h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office will issue on September 22, 2020 U.S. Patent No....
NeuroMetrix Reports Scientific Presentation at the PAINWeek 2020 Live Virtual Conference
04 sept. 2020 07h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it will present a scientific poster at the PAINWeek 2020 Live Virtual Conference to be...
NeuroMetrix Reports Publication of Study Validating DPNCheck® Staging of Diabetic Peripheral Neuropathy Severity
01 sept. 2020 13h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the publication of a large study demonstrating that DPNCheck effectively determines the severity of...
NeuroMetrix Reports that Quell® is to be Evaluated for Chemotherapy-Induced Peripheral Neuropathy in NIH-Funded Clinical Trial
20 août 2020 14h11 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell device will be used in an NIH-funded, multi-site randomized controlled trial (RCT) of...